Month: May 2022

– Multiple milestones anticipated for 2022 including submission of IND and/or CTA for DB-OTO, top-line results from interim analysis of Phase 1b trial of DB-020 for cisplatin-induced hearing loss and product candidate selection for AAV.103 program – – New preclinical data presented at the 45th Annual Association for Research in Otolaryngology Conference (ARO) supporting DB-OTO and emphasizing platform focus on cell-selective transgene expression – – Preclinical data to be presented at the American Society of Gene and Cell Therapy (ASGCT) 25th Annual Meeting supporting DB-OTO, AAV.103 and AAV.104 – BOSTON, May 12, 2022 (GLOBE NEWSWIRE) — Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and...

Delivered first clinical data demonstrating target engagement and translation of PN chemistry’s impact in clinic; Adapting ongoing Phase 1b/2a FOCUS-C9 clinical trial to optimize dose level and frequency, with additional single and multidose data expected throughout 2022 Clinical data also expected in 2022 from Huntington’s disease (WVE-003) and Duchenne muscular dystrophy (WVE-N531) trials Robust preclinical datasets for first-in-class AATD program demonstrate restoration of levels of AAT relevant for potential lung protection and reduction of liver-damaging aggregates with GalNAc AIMers; IND enabling toxicology studies for lead AATD candidate on-track to initiate in 3Q 2022 Wave to host investor conference call and webcast at 8:30 a.m. ET today CAMBRIDGE, Mass., May 12, 2022 (GLOBE NEWSWIRE) — Wave Life Sciences Ltd. (Nasdaq:...

Record Q2 Sales of $4.9 million, Q2 Net Earnings of $0.7 million MISSISSAUGA, Ontario, May 12, 2022 (GLOBE NEWSWIRE) — Microbix Biosystems Inc. (TSX: MBX, OTCQX: MBXBF, Microbix®), a life sciences innovator, manufacturer, and exporter, reports results for its second quarter and first half of fiscal 2022 ended March 31, 2022 (“Q2” and “H2”), with record sales and strong earnings, plus ongoing progress upon its strategic goal of increasing the proportion of revenues derived from medical devices to thereby continue growing sales, margins, and earnings. Management Discussion Q2 revenues achieved a record level of $4.9 million, up 12% from Q2 2021, as Microbix continues to emphasize operational excellence and the sale of innovative, proprietary, and branded medical devices. Microbix’s viral transport medium (branded “DxTM™”) contributed...

Higher Commodity Prices, Cost Discipline Drive a 127% Increase in Net Operating IncomeGrowing Interest in Proposed LNG Project NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR DISSEMINATION IN UNITED STATES HighlightsDuring Q1 2022:Generated Net Operating Income1 (“NOI”) of $47.3 million ($0.30 per basic and fully diluted share), up 127% from the comparable period in 2021; Generated Adjusted Funds Flow from Operations1 (“AFFO”) of $45.1 million ($0.29 per basic and fully diluted share), up 203%; generated net income of $10.5 million ($0.07 per basic and fully diluted share), up 154% from the comparable period in 2021; Generated petroleum and natural gas revenue of $129.8 million, up 48% from the comparable period in 2021; Netback per boe increased 146% to $12.98/boe from $5.27/boe in the comparable period in 2021; Total...

Quarter highlighted by progress with vilobelimab in several indications:Encouraging Phase III topline results reported in patients with severe COVID-19; discussions with regulatory authorities already underway Final data from Phase IIa open-label study in patients with pyoderma gangrenosum presented at 2022 AAD Annual Meeting; end-of-Phase II meeting with FDA scheduled for mid-2022 In Phase II trial in cutaneous squamous cell carcinoma, second dosing cohort of combination arm started; enrollment in monotherapy arm continuing with 8 patients enrolled with data expected in Q3 2022 Clinical development in hidradenitis suppurativa and ANCA-associated vasculitis halted for the time beingIntroduced new pipeline program, INF904, an oral small molecule inhibitor of C5aR; planned to enter the clinic later this year Cash, cash equivalents...